- Home
- WKSP vs BLRX Comparison
WKSP vs BLRX Comparison
Compare WKSP & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WKSP | BLRX |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Israel |
| Employees | 81 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.6M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | WKSP | BLRX |
|---|---|---|
| Price | $0.68 | $3.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.25 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 544.8K | 47.7K |
| Earning Date | 05-15-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $131.96 | N/A |
| Revenue Next Year | $24.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $2.15 |
| 52 Week High | $4.90 | $6.59 |
Technical Indicators
Market Signals| Indicator | WKSP | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 56.98 |
| Support Level | $0.70 | $3.11 |
| Resistance Level | $1.03 | $3.45 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 8.87 | 56.64 |
Price Performance
Historical ComparisonAbout WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.